Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.67 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746095 | 0.98 | KCNA3 (0.64) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL11068531 | 0.98 | KCNA3 (0.64) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL358609 | 0.98 | KCNA3 (0.64) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL29394668 | 0.96 | KCNA3 (0.61) | KCNA3RARBHPGDHDAC3HDAC4 | |
| Ethylene SCHEMBL28162451 | 0.94 | KCNA3 (0.59) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL7449489 | 0.94 | KCNA3 (0.62) | KCNA3RARBHPGDHDAC3HDAC4 | |
| Ethylene Glycol SCHEMBL27943432 | 0.91 | KCNA3 (0.55) | KCNA3RARBHPGDHDAC3HDAC4 | |
| Oxirane SCHEMBL8670366 | 0.89 | KCNA3 (0.53) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL11818753 | 0.89 | KCNA3 (0.53) | KCNA3RARBHPGDHDAC3HDAC4 | |
| SCHEMBL27936313 | 0.89 | KCNA3 (0.53) | KCNA3RARBHPGDHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| US-4066707-A | METHOD FOR MANUFACTURE OF DIPHENOLS AND MONOALKYL ETHERS OF DIPHENOLS | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JA) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | KCNA3 1722/4885RARB 1617/4885HPGD 952/4885 |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | KCNA3 4233/4885RARB 3875/4885HPGD 3221/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | KCNA3 2485/4885RARB 672/4885HPGD 524/4885 |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | FAAH, FAAH2, CNR2 | KCNA3 1676/4885RARB 2377/4885HPGD 1848/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | KCNA3 1742/4885RARB 1241/4885HPGD 833/4885 |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | KCNA3 4233/4885RARB 3875/4885HPGD 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.